Thuja capital portfolio company ArGEN-X raises EUR 9.5M

14-Sep-2009 - Netherlands

Thuja Capital's portfolio company ArGEN-X, a research stage biopharmaceutical company, has successfully closed an equity financing round, raising EUR 9.5 million. The financing round is one of the largest in its kind in Europe in the last 12 months.

The deal was co-led by Forbion Capital Partners and Life Sciences Partners (LSP). Christina Takke for Forbion Capital Partners and John de Koning for LSP have joined the arGEN-X Supervisory Board. Other members of the syndicate are KBC Private Equity (Belgium), BioGeneration Ventures (The Netherlands) and existing shareholders Erasmus MC Biomedical Fund and Thuja Capital Healthcare Funds.

ArGEN-X was seed funded in April 2008 by Thuja Capital Healthcare Seed Fund in collaboration with Erasmus MC Biomedical Fund.

Other news from the department business & finance

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance